Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling

Cardiovascular Research

Volumn 110, Issue 3, 2016, Pages 381-394

  Hille, Susanne ^a,b   Dierck, Franziska ^a,b   Kühl, Constantin ^a,b   Sosna, Justyna ^c   Adam Klages, Sabine ^c   Adam, Dieter ^c   Lüllmann Rauch, Renate ^c   Frey, Norbert ^a,b   Kuhn, Christian ^a,b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

Cell cycle; Dyrk1a; Heart failure; Hypertrophy; Rb E2f signalling

Indexed keywords

CYCLINE; D CYCLIN PROTEIN; DUAL SPECIFICITY TYROSINE (Y) PHOSPHORYLATION REGULATED KINASE 1A; PROTEASOME; PROTEIN KINASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; CYCLIN D; DYRK KINASE; PROTEIN BINDING; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR MORTALITY; CELL CYCLE; CELL CYCLE PROGRESSION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME DEGRADATION; GENE OVEREXPRESSION; HEART VENTRICLE HYPERTROPHY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CARDIOMEGALY; CELL PROLIFERATION; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HEART FAILURE; HEK293 CELL LINE; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; RETINOBLASTOMA; TIME FACTOR; TRANSGENIC MOUSE; WISTAR RAT;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHY, DILATED; CELL CYCLE; CELL PROLIFERATION; CYCLIN D; DISEASE MODELS, ANIMAL; E2F TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HEART FAILURE; HEK293 CELLS; HUMANS; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; RATS, WISTAR; RETINOBLASTOMA; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84973316009     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvw074     Document Type: Article

References (70)

1. Song WJ, Sternberg LR, Kasten-Sportes C, Keuren ML, Chung SH, Slack AC, Miller DE, GloverTW, Chiang PW, Lou L, Kurnit DM. Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome "critical region". Genomics 1996;38:331-339.
2. Shindoh N, Kudoh J, Maeda H, Yamaki A, Minoshima S, Shimizu Y, Shimizu N. Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21. Biochem Biophys Res Commun 1996;225: 92-99.
3. Soundararajan M, Roos AK, Savitsky P, Filippakopoulos P, Kettenbach AN, Olsen JV, Gerber SA, Eswaran J, Knapp S, Elkins JM. Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. Structure 2013;21:986-996.
4. Aranda S, Laguna A, de la Luna S. DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J 2011;25:449-462.
5. Park J, Song WJ, Chung KC. Function and regulation of Dyrk1A: towards understanding Down syndrome. Cell Mol Life Sci 2009;66:3235-3240.
6. Fotaki V, Dierssen M, Alcantara S, Martinez S, Marti E, Casas C, Visa J, Soriano E, Estivill X, Arbones ML. Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol 2002;22: 6636-6647.
7. Arque G, Fotaki V, Fernandez D, Martinez de Lagran M, Arbones ML, Dierssen M. Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). PLoS One 2008;3:e2575.
8. Smith DJ, Stevens ME, Sudanagunta SP, Bronson RT, Makhinson M, Watabe AM, O'Dell TJ, Fung J,Weier HU, Cheng JF, Rubin EM. Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet 1997;16:28-36.
9. Altafaj X, Dierssen M, Baamonde C, Marti E, Visa J, Guimera J, Oset M, Gonzalez JR, Florez J, Fillat C, Estivill X. Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), amurine model of Down's syndrome. Hum Mol Genet 2001;10:1915-1923.
10. Freeman SB, Bean LH, Allen EG, Tinker SW, Locke AE, Druschel C, Hobbs CA, Romitti PA, Royle MH, Torfs CP, Dooley KJ, Sherman SL. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genet Med 2008;10:173-180.
11. Arron JR, Winslow MM, Polleri A, Chang CP,Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef IA, Crabtree GR. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006; 441:595-600.
12. Gwack Y, Sharma S, Nardone J, Tanasa B, Iuga A, Srikanth S, Okamura H, Bolton D, Feske S, Hogan PG, Rao A. A genome-wide Drosophila RNAi screen identifies DYRKfamily kinases as regulators of NFAT. Nature 2006;441:646-650.
13. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
14. Kuhn C, Frank D, Will R, Jaschinski C, Frauen R, Katus HA, Frey N. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy. J Biol Chem 2009;284:17320-17327.
15. Grebe C, Klingebiel TM, Grau SP, Toischer K, Didie M, Jacobshagen C, Dullin C, Hasenfuss G, Seidler T. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo. Cardiovasc Res 2011;90:521-528.
16. Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD. Impaired cardiac hypertrophic response in Calcineurin Abeta-deficient mice. Proc Natl Acad Sci USA 2002;99:4586-4591.
17. De Windt LJ, Lim HW, Bueno OF, Liang Q, Delling U, Braz JC, Glascock BJ, Kimball TF, del Monte F, Hajjar RJ, Molkentin JD. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2001;98:3322-3327.
18. Gulick J, Subramaniam A, Neumann J, Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J Biol Chem 1991;266:9180-9185.
19. Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, Kern R, Koegl M. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteomics 2005;4:205-213.
20. Rangrez AY, Bernt A, Poyanmehr R, Harazin V, Boomgaarden I, Kuhn C, Rohrbeck A, Frank D, Frey N. Dysbindin is a potent inducer of RhoA-SRF-mediated cardiomyocyte hypertrophy. J Cell Biol 2013;203:643-656.
21. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol 2013;14:518-528.
22. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ Res 2005;96:110-118.
23. ZhongW, Mao S, Tobis S, Angelis E, Jordan MC, Roos KP, Fishbein MC, de Alboran IM, MacLellan WR. Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway. EMBO J 2006;25:3869-3879.
24. Okui M, Ide T, Morita K, Funakoshi E, Ito F, Ogita K, Yoneda Y, Kudoh J, Shimizu N. High-level expression of the Mnb/Dyrk1A gene in brain and heart during rat early development. Genomics 1999;62:165-171.
25. Brooks G, Poolman RA, McGill CJ, Li JM. Expression and activities of cyclins and cyclindependent kinases in developing rat ventricular myocytes. J Mol Cell Cardiol 1997;29: 2261-2271.
26. Chen JY, Lin JR, Tsai FC, Meyer T. Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Mol Cell 2013;52:87-100.
27. Najas S, Arranz J, Lochhead PA, Ashford AL, Oxley D, Delabar JM, Cook SJ, Barallobre MJ, Arbones ML. DYRK1A-mediated cyclin D1 degradation in neural stem cells contributes to the neurogenic cortical defects in Down syndrome. EBioMedicine 2015;2:120-134.
28. Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor FJ, Becker W. The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation. Cell Cycle 2014;13: 2084-2100.
29. Thompson BJ, Bhansali R, Diebold L, Cook DE, Stolzenburg L, Casagrande AS, Besson T, Leblond B, Desire L, Malinge S, Crispino JD. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med 2015;21:953-970.
30. Xiong Y, Menninger J, Beach D, Ward DC. Molecular cloning and chromosomal mapping of CCND genes encoding human D-type cyclins. Genomics 1992;13:575-584.
31. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11:957-972.
32. Kida A, Kakihana K, Kotani S, Kurosu T, Miura O. Glycogen synthase kinase-3beta and p38 phosphorylate cyclin D2 on Thr280 to trigger its ubiquitin/proteasome-dependent degradation in hematopoietic cells. Oncogene 2007;26:6630-6640.
33. Naderi S, Gutzkow KB, Lahne HU, Lefdal S, Ryves WJ, Harwood AJ, Blomhoff HK. cAMP-induced degradation of cyclin D3 through association with GSK-3beta. J Cell Sci 2004;117:3769-3783.
34. Busk PK, Bartkova J, Strom CC, Wulf-Andersen L, Hinrichsen R, Christoffersen TE, Latella L, Bartek J, Haunso S, Sheikh SP. Involvement of cyclin D activity in left ventricle hypertrophy in vivo and in vitro. Cardiovasc Res 2002;56:64-75.
35. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
36. Flink IL, Oana S, Maitra N, Bahl JJ, Morkin E. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes. J Mol Cell Cardiol 1998;30: 563-578.
37. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997;272:12738-12746.
38. Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006;25:5220-5227.
39. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999;98:859-869.
40. Pelka P, Miller MS, Cecchini M, Yousef AF, Bowdish DM, Dick F, Whyte P, Mymryk JS. Adenovirus E1A directly targets the E2F/DP-1 complex. J Virol 2011;85:8841-8851.
41. Bracken AP, Ciro M, Cocito A, Helin K. E2F target genes: unraveling the biology. Trends Biochem Sci 2004;29:409-417.
42. Yabut O, Domogauer J, D'Arcangelo G. Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J Neurosci 2010;30:4004-4014.
43. Hammerle B, Ulin E, Guimera J, BeckerW, Guillemot F, Tejedor FJ. Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development 2011; 138:2543-2554.
44. Liu Q, Liu N, Zang S, Liu H,Wang P, Ji C, Sun X. Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc. PLoS One 2014;9:e98853.
45. Ahuja P, Sdek P, MacLellan WR. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 2007;87:521-544.
46. Vara D, Bicknell KA, Coxon CH, Brooks G. Inhibition of E2F abrogates the development of cardiac myocyte hypertrophy. J Biol Chem 2003;278:21388-21394.
47. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
48. Wei Y, Mizzen CA, Cook RG, Gorovsky MA, Allis CD. Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci USA 1998;95:7480-7484.
49. Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac myocytes from hyperplasia to hypertrophy during postnatal development. J Mol Cell Cardiol 1996;28: 1737-1746.
50. Thornburg K, Jonker S, O'Tierney P, Chattergoon N, Louey S, Faber J, Giraud G. Regulation of the cardiomyocyte population in the developing heart. Prog Biophys Mol Biol 2011;106:289-299.
51. Soonpaa MH, Kim KK, Pajak L, Franklin M, Field LJ. Cardiomyocyte DNA synthesis and binucleation during murine development. Am J Physiol 1996;271:H2183-H2189.
52. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, Perriard JC, Chien KR, Caroni P. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997;88:393-403.
53. Ng WA, Grupp IL, Subramaniam A, Robbins J. Cardiac myosin heavy chain mRNA expression and myocardial function in the mouse heart. Circ Res 1991;68:1742-1750.
54. Litovchick L, Florens LA, Swanson SK, Washburn MP, DeCaprio JA. DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 2011;25:801-813.
55. Paradis AN, Gay MS, Zhang L. Binucleation of cardiomyocytes: the transition from a proliferative to a terminally differentiated state. Drug Discov Today 2014;19:602-609.
56. de Vries WB, Bal MP, Homoet-van der Kraak P, Kamphuis PJ, van der Leij FR, Baan J, Steendijk P, deWeger RA, van Bel F, van Oosterhout MF. Suppression of physiological cardiomyocyte proliferation in the rat pup after neonatal glucocorticosteroid treatment. Basic Res Cardiol 2006;101:36-42.
57. de Vries WB, van der Leij FR, Bakker JM, Kamphuis PJ, van Oosterhout MF, Schipper ME, Smid GB, Bartelds B, van Bel F. Alterations in adult rat heart after neonatal dexamethasone therapy. Pediatr Res 2002;52:900-906.
58. Bal MP, de Vries WB, van Oosterhout MF, Baan J, van derWall EE, van Bel F, Steendijk P. Long-term cardiovascular effects of neonatal dexamethasone treatment: hemodynamic follow-up by left ventricular pressure-volume loops in rats. J Appl Physiol (1985) 2008; 104:446-450.
59. Bal MP, de Vries WB, Steendijk P, Homoet-van der Kraak P, van der Leij FR, Baan J, van Oosterhout MF, van Bel F. Histopathological changes of the heart after neonatal dexamethasone treatment: studies in 4-, 8-, and 50-week-old rats. Pediatr Res 2009;66: 74-79.
60. Ciemerych MA, Kenney AM, Sicinska E, Kalaszczynska I, Bronson RT, Rowitch DH, Gardner H, Sicinski P. Development of mice expressing a single D-type cyclin. Genes Dev 2002;16:3277-3289.
61. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, Geng Y, Yu Q, Bhattacharya S, Bronson RT, Akashi K, Sicinski P. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004;118:477-491.
62. Berthet C, Klarmann KD, Hilton MB, Suh HC, Keller JR, Kiyokawa H, Kaldis P. Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation. Dev Cell 2006;10:563-573.
63. Swiss VA, Casaccia P. Cell-context specific role of the E2F/Rb pathway in development and disease. Glia 2010;58:377-390.
64. Wang P, Alvarez-Perez JC, Felsenfeld DP, Liu H, Sivendran S, Bender A, Kumar A, Sanchez R, Scott DK, Garcia-Ocana A, Stewart AF. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. Nat Med 2015;21:383-388.
65. Hassink RJ, Pasumarthi KB, Nakajima H, Rubart M, Soonpaa MH, de la Riviere AB, Doevendans PA, Field LJ. Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovasc Res 2008;78:18-25.
66. Nozato T, Ito H, Tamamori M, Adachi S, Abe S, Marumo F, Hiroe M. G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. Jpn Circ J 2000;64:595-601.
67. Hinrichsen R, Hansen AH, Haunso S, Busk PK. Phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy. Cell Prolif 2008;41: 813-829.
68. Angelis E, Garcia A, Chan SS, Schenke-Layland K, Ren S, Goodfellow SJ, Jordan MC, Roos KP, White RJ, MacLellan WR. A cyclin D2-Rb pathway regulates cardiac myocyte size and RNA polymerase III after biomechanical stress in adult myocardium. Circ Res 2008;102:1222-1229.
69. da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. Nat Cell Biol 2010;12:1220-1227.
70. Rothermel BA, Vega RB, Williams RS. The role of modulatory calcineurin-interacting proteins in calcineurin signaling. Trends Cardiovasc Med 2003;13:15-21.